Aptevo Therapeutics (NASDAQ:APVO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO opened at $0.77 on Thursday. Aptevo Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $91.96. The business has a 50-day simple moving average of $4.79 and a two-hundred day simple moving average of $7.85.

Institutional Investors Weigh In On Aptevo Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP purchased a new stake in shares of Aptevo Therapeutics during the 4th quarter valued at about $29,000. Virtu Financial LLC purchased a new stake in shares of Aptevo Therapeutics during the 2nd quarter valued at about $46,000. Citadel Advisors LLC purchased a new stake in shares of Aptevo Therapeutics during the 3rd quarter valued at about $51,000. Bank of New York Mellon Corp bought a new position in shares of Aptevo Therapeutics during the 1st quarter valued at approximately $152,000. Finally, Renaissance Technologies LLC grew its stake in shares of Aptevo Therapeutics by 18.7% during the 2nd quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock valued at $250,000 after acquiring an additional 11,000 shares during the period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.